Caredx, Inc.
A precision medicine company focused on keeping transplanted organs healthy. CareDx makes non-invasive blood tests — AlloMap Heart and the AlloSure Kidney, Heart, and Lung panels — that monitor transplant recipients for early signs of rejection without a biopsy, along with HLA typing kits and AlloSeq gene-sequencing tools used to match donors and recipients. Its Ottr and MedActionPlan software help transplant teams track and manage patient care between visits.
Bought 1.54M · Sold 108.6K
Bought 115.0K
Granted 14.4K · Bought 53.3K
Bought 52.8K
Granted 470.8K · Sold 124.4K
Granted 457.1K
Granted 744.8K · Sold 179.3K
Granted 390.1K · Sold 265
Granted 1.56M · Bought 37.6K · Sold 1.13M
Granted 411.8K · Sold 95.3K
Granted 245.9K
Granted 318.2K · Bought 25.0K · Sold 158.0K
Granted 185.9K
Granted 154.5K
Granted 191.1K · Sold 85.0K
Granted 345.3K · Bought 725 · Sold 193.7K
Granted 129.6K · Bought 10.0K · Sold 90.2K
Granted 60.5K · Sold 35.6K
Granted 289.1K · Sold 189.7K
Granted 82.9K
Granted 160.3K · Sold 116.9K
Granted 153.4K · Sold 109.3K
Granted 104.8K · Sold 45.8K
Granted 101.8K · Sold 21.5K
Granted 41.0K · Bought 7.0K
Granted 21.9K
Granted 38.1K · Bought 600 · Sold 10.6K
Granted 34.4K · Bought 5.0K
Granted 37.2K
Granted 48.8K · Sold 22.7K
Granted 32.8K · Sold 9.1K
Granted 21.0K
Granted 21.0K
Granted 17.7K
Granted 15.8K
Granted 11.0K
Granted 10.0K
Granted 10.0K · Bought 10.0K
Granted 29.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gagnon Neil10% owner · 133 transactions | — | 2.92Mas of Nov 2018 | — | 1.54M | 108.6K |
| Bonderman David +2 co-filers10% owner · 2 transactions | — | 960.1Kas of Jul 2014 | — | 115.0K | — |
| Byers Brook HFormer Director · 20 transactions | — | 773.1Kas of Jul 2016 | 14.4K | 53.3K | — |
| Kleiner Perkins Caufield & Byers X A LP +2 co-filers10% owner · 6 transactions | — | 751.2Kas of Jul 2014 | — | 52.8K | — |
| Hanna John Walter JRPresident and CEO, Director · 21 transactions | — | 662.0K | 470.8K | — | 124.4K |
| Ronai AbrahamSee Remarks · 7 transactions | — | 516.0Kas of Sep 2023 | 457.1K | — | — |
| Seeto ReginaldSee Remarks, Director · 92 transactions | — | 479.2Kas of Oct 2023 | 744.8K | — | 179.3K |
| Jain AbhishekChief Financial Officer · 26 transactions | — | 319.7Kas of Aug 2025 | 390.1K | — | 265 |
| Maag PeterDirector · 236 transactions | — | 308.8Kas of Jul 2025 | 1.56M | 37.6K | 1.13M |
| Johnson Alexander LSee Remarks · 35 transactions | — | 306.5Kas of Aug 2024 | 411.8K | — | 95.3K |
| Kennedy KeithCFO & COO · 8 transactions | — | 221.5K | 245.9K | — | — |
| Goldberg MichaelDirector · 92 transactions | — | 195.7K | 318.2K | 25.0K | 158.0K |
| Meng JessicaChief Commercial Officer · 7 transactions | — | 169.4K | 185.9K | — | — |
| Cohen Fred EDirector · 30 transactions | — | 165.1K | 154.5K | — | — |
| Bickerstaff GeorgeDirector · 66 transactions | — | 154.1K | 191.1K | — | 85.0K |
| Bell Michael BrianChief Financial Officer · 65 transactions | — | 131.6Kas of Nov 2020 | 345.3K | 725 | 193.7K |
| Nelles Mitchell JChief Operating Officer · 20 transactions | — | 126.5Kas of Jul 2018 | 129.6K | 10.0K | 90.2K |
| Novack Jeffrey AdamSecretary and General Counsel · 37 transactions | — | 112.6K | 60.5K | — | 35.6K |
| King SashaChief Marketing Officer · 102 transactions | — | 78.4Kas of Aug 2022 | 289.1K | — | 189.7K |
| Smith NathanChief Financial Officer · 4 transactions | — | 75.0K | 82.9K | — | — |
| Hagstrom William ADirector · 40 transactions | — | 73.4Kas of Jun 2025 | 160.3K | — | 116.9K |
| Yee James PChief Medical Officer · 26 transactions | — | 62.0Kas of Jul 2019 | 153.4K | — | 109.3K |
| Cournoyer ChristineDirector · 27 transactions | — | 58.9K | 104.8K | — | 45.8K |
| Snyderman RalphDirector · 44 transactions | — | 58.2Kas of Oct 2022 | 101.8K | — | 21.5K |
| Ludlum KenChief Financial Officer · 4 transactions | — | 48.0Kas of Jan 2016 | 41.0K | 7.0K | — |
| Riggsbee Richard BryanDirector · 2 transactions | — | 39.3K | 21.9K | — | — |
| Torres Arthur ADirector · 7 transactions | — | 38.7K | 38.1K | 600 | 10.6K |
| Dhingra AnkurChief Financial Officer · 4 transactions | — | 38.1Kas of Mar 2022 | 34.4K | 5.0K | — |
| Gunasekaran SureshDirector · 2 transactions | — | 37.2K | 37.2K | — | — |
| Valantine HannahDirector · 11 transactions | — | 36.7K | 48.8K | — | 22.7K |
| Colon GraceDirector · 10 transactions | — | 29.1Kas of Jun 2023 | 32.8K | — | 9.1K |
| Meyer Matthew J.Chief Business Officer · 2 transactions | — | 23.0Kas of Jan 2016 | 21.0K | — | — |
| Sninsky John JosephChief Scientific Officer · 4 transactions | — | 22.3Kas of Jan 2018 | 21.0K | — | — |
| Miller Douglas SDirector · 4 transactions | — | 17.7Kas of Apr 2017 | 17.7K | — | — |
| Abernethy AmyDirector · 4 transactions | — | 15.8Kas of Jan 2019 | 15.8K | — | — |
| DeFonzo JoshuaChief Commercial Officer · 1 transaction | — | 11.0Kas of Jan 2016 | 11.0K | — | — |
| Constanti CharlesChief Financial Officer · 1 transaction | — | 10.0Kas of Feb 2017 | 10.0K | — | — |
| Whitson ToddChief Commercial Officer · 2 transactions | — | 10.0Kas of Sep 2016 | 10.0K | 10.0K | — |
| Karlsson AndersChief Commercial Officer · 3 transactions | — | 9.6Kas of Jan 2018 | 29.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -867.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.